Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel...
Clinical Trial
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
~35% of erectile dysfunction patients in a $3.2 billion market are non-responders to brands including Viagra and Cialis, and these...
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical...
Applied Therapeutics Announces Corporate Updates
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated...
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting...
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...
Medicure Reports Financial Results for Quarter Ended September 30, 2025
WINNIPEG, MB / ACCESS Newswire / November 19, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused...
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"),...
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready)...
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development...
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company...
CASI Pharmaceuticals Announces Changes in Board Governance
James Huang appointed as Non-Executive Chairman of CASI Board of Directors SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November...
Precise Bio Achieves World’s First 3D-Bio-Printed Corneal Implant
Successful first human implantation marks a transformational moment in ophthalmology and regenerative medicine Breakthrough marks key clinical milestone for Precise...
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the...
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage...
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy PipelineBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE)...
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics...
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success...
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
Teva Launches Teva Rise Teva Launches Rise - Global Open Innovation Platform First cohort features 7 real-world challenges across R&D,...
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...